These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33157050)

  • 1. Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.
    Zhao W; Li J; Chen MM; Luo Y; Ju Z; Nesser NK; Johnson-Camacho K; Boniface CT; Lawrence Y; Pande NT; Davies MA; Herlyn M; Muranen T; Zervantonakis IK; von Euw E; Schultz A; Kumar SV; Korkut A; Spellman PT; Akbani R; Slamon DJ; Gray JW; Brugge JS; Lu Y; Mills GB; Liang H
    Cancer Cell; 2020 Dec; 38(6):829-843.e4. PubMed ID: 33157050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
    Ali M; Khan SA; Wennerberg K; Aittokallio T
    Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.
    Li J; Zhao W; Akbani R; Liu W; Ju Z; Ling S; Vellano CP; Roebuck P; Yu Q; Eterovic AK; Byers LA; Davies MA; Deng W; Gopal YN; Chen G; von Euw EM; Slamon D; Conklin D; Heymach JV; Gazdar AF; Minna JD; Myers JN; Lu Y; Mills GB; Liang H
    Cancer Cell; 2017 Feb; 31(2):225-239. PubMed ID: 28196595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
    Jimenez CR; Verheul HM
    Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.
    Seashore-Ludlow B; Rees MG; Cheah JH; Cokol M; Price EV; Coletti ME; Jones V; Bodycombe NE; Soule CK; Gould J; Alexander B; Li A; Montgomery P; Wawer MJ; Kuru N; Kotz JD; Hon CS; Munoz B; Liefeld T; Dančík V; Bittker JA; Palmer M; Bradner JE; Shamji AF; Clemons PA; Schreiber SL
    Cancer Discov; 2015 Nov; 5(11):1210-23. PubMed ID: 26482930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays.
    Chen MM; Li J; Mills GB; Liang H
    JCO Clin Cancer Inform; 2020 Apr; 4():357-366. PubMed ID: 32330068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View.
    Dar KB; Bhat AH; Amin S; Anjum S; Reshi BA; Zargar MA; Masood A; Ganie SA
    Curr Cancer Drug Targets; 2019; 19(6):430-448. PubMed ID: 30073927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins.
    Cruz IN; Coley HM; Kramer HB; Madhuri TK; Safuwan NA; Angelino AR; Yang M
    Cancer Genomics Proteomics; 2017 Jan; 14(1):35-51. PubMed ID: 28031236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation characterization of the Cancer Cell Line Encyclopedia.
    Ghandi M; Huang FW; Jané-Valbuena J; Kryukov GV; Lo CC; McDonald ER; Barretina J; Gelfand ET; Bielski CM; Li H; Hu K; Andreev-Drakhlin AY; Kim J; Hess JM; Haas BJ; Aguet F; Weir BA; Rothberg MV; Paolella BR; Lawrence MS; Akbani R; Lu Y; Tiv HL; Gokhale PC; de Weck A; Mansour AA; Oh C; Shih J; Hadi K; Rosen Y; Bistline J; Venkatesan K; Reddy A; Sonkin D; Liu M; Lehar J; Korn JM; Porter DA; Jones MD; Golji J; Caponigro G; Taylor JE; Dunning CM; Creech AL; Warren AC; McFarland JM; Zamanighomi M; Kauffmann A; Stransky N; Imielinski M; Maruvka YE; Cherniack AD; Tsherniak A; Vazquez F; Jaffe JD; Lane AA; Weinstock DM; Johannessen CM; Morrissey MP; Stegmeier F; Schlegel R; Hahn WC; Getz G; Mills GB; Boehm JS; Golub TR; Garraway LA; Sellers WR
    Nature; 2019 May; 569(7757):503-508. PubMed ID: 31068700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target Inhibition Maps Based on Responses to Kinase Inhibitors.
    Berlow N; Pal R
    Methods Mol Biol; 2017; 1636():507-522. PubMed ID: 28730499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.
    Niu J; Wang X; Qu J; Mager DE; Straubinger RM
    BMC Cancer; 2020 Oct; 20(1):1024. PubMed ID: 33097020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting chemosensitivity using drug perturbed gene dynamics.
    Mannheimer JD; Prasad A; Gustafson DL
    BMC Bioinformatics; 2021 Jan; 22(1):15. PubMed ID: 33413081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
    Srivas R; Shen JP; Yang CC; Sun SM; Li J; Gross AM; Jensen J; Licon K; Bojorquez-Gomez A; Klepper K; Huang J; Pekin D; Xu JL; Yeerna H; Sivaganesh V; Kollenstart L; van Attikum H; Aza-Blanc P; Sobol RW; Ideker T
    Mol Cell; 2016 Aug; 63(3):514-25. PubMed ID: 27453043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein and lysate array technologies in cancer research.
    Spurrier B; Honkanen P; Holway A; Kumamoto K; Terashima M; Takenoshita S; Wakabayashi G; Austin J; Nishizuka S
    Biotechnol Adv; 2008; 26(4):361-9. PubMed ID: 18514460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
    Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
    Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iTRAQ‑based proteomics analysis of the therapeutic effects of combined anticancer bioactive peptides and oxaliplatin on gastric cancer cells.
    Xu Y; Li X; Su X
    Oncol Rep; 2020 Jan; 43(1):201-217. PubMed ID: 31746436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.